CompletedNCT03345979

A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia

This study evaluated the safety and effectiveness of Paliperidone Palmitate for people with schizophrenia.

Medication studyAges 18–65United States

The study in practice

Understand this study

This study evaluated the safety and effectiveness of Paliperidone Palmitate for people with schizophrenia.

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations: Little Rock and 15 more locationsSee all locations and recruitment
Study phase: Phase 3

Study clarity

Study start dateStarted: November 15, 2017

Recruitment status: Completed
Enrollment listed in the registry: 200
Sponsor: Alkermes, Inc.
Sponsor type: Other organization
Study type: Drug
Intervention type: COMBINATION_PRODUCT, Medication / drug
Study phase: Phase 3
Locations: United States
Age range: From 18 Years to 65 Years
Official registry ID: NCT03345979
Official title: Show the full official title
A Phase 3b, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia in Subjects Hospitalized for Acute Exacerbation

Completed

Little Rock · Rogers · Cerritos

13 more locations

FAQ

What did researchers investigate?

This study evaluated the safety and effectiveness of Paliperidone Palmitate for people with schizophrenia.

Who is behind this study?

The study sponsor is Alkermes, Inc.

Did this study involve medication?

Yes. The study involved medication, including Paliperidone Palmitate.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.